The Bloodwork to Get Before Starting Peptides in Houston

There is a version of starting peptides that skips straight to the vial: someone reads a forum thread, orders a compound, and begins injecting without a single number to their name. It is common, and it is a mistake. Bloodwork done before you start is the quiet, unglamorous foundation of doing this responsibly. It is the reference photograph you take of your metabolism on a normal day, so that if something drifts later, a physician can tell whether the peptide moved it or whether it was always that way. Without a baseline, every future lab is a number floating in space, impossible to interpret with confidence.

This guide walks through the labs most often discussed in the peptide literature and clinical practice as a sensible before starting picture, what each one actually measures, and why it earns a place on the order. We will keep the framing honest throughout: most of the peptides people are curious about are not FDA-approved for human use, the human evidence is often thinner than the marketing, and nothing here is a prescription. It is a map of the conversation to have with a licensed physician — ideally one you can see in person, here in Houston, who can put a stethoscope on the plan and order the draws through a real lab.

Why a baseline matters more than any single result

The purpose of pre-treatment labs is not to pass or fail a test. It is to establish your personal normal. Reference ranges printed on a lab report describe a population; they tell you where most people land, but they do not tell you where you land on an ordinary Tuesday. A fasting glucose of 95 mg/dL means something very different in a person whose baseline was 82 versus a person whose baseline was 97. The first has moved; the second has not. You cannot know which story is yours unless you took the picture first.

This matters acutely with the peptides people gravitate toward, because several of them act on systems that show up in routine bloodwork. Growth-hormone secretagogues — the ipamorelin, tesamorelin, and MK-677 family — work by prompting your own pituitary to release more growth hormone, which in turn raises insulin-like growth factor 1, or IGF-1. That is the intended effect. But the same pathway can blunt insulin sensitivity and edge fasting glucose upward in some people. If you never measured glucose, IGF-1, or an HbA1c beforehand, you have no way to see that shift when it happens, and no way to reassure yourself when it does not.

The core panel most physicians will want to see

There is no single official peptide panel, because peptides are not a single approved therapy. But if you assemble what appears again and again in clinical monitoring guidance for growth-hormone and metabolic agents, a recognizable core emerges. Think of it in layers: a general-health foundation that any responsible physician would draw before starting anything, and then a set of targeted markers that speak specifically to the systems peptides touch.

The foundation starts with a complete blood count, or CBC. This counts your red cells, white cells, and platelets. It is the least glamorous test on the list and one of the most important, because it screens broadly — anemia, signs of infection, platelet abnormalities — and gives context for fatigue or recovery complaints people sometimes hope a peptide will fix. If your tiredness is actually iron-deficiency anemia, no secretagogue is going to solve it, and the CBC is what catches that before you spend months chasing the wrong lever.

Next is the comprehensive metabolic panel, the CMP. This is a fourteen-marker workhorse covering kidney function (BUN, creatinine, eGFR), liver enzymes (ALT, AST, ALP, bilirubin), electrolytes (sodium, potassium, chloride, CO2), calcium, total protein, albumin, and glucose. It tells a physician whether your kidneys and liver — the organs that ultimately handle the metabolic load of any compound — are working normally before you add anything. Elevated liver enzymes or reduced kidney function at baseline change the entire risk calculation and are exactly the kind of finding you want in hand before, not after. Peptides are, after all, still substances your body has to process and clear, and the CMP is the closest thing you have to a dashboard for the two organs doing most of that work. A mildly elevated ALT that nobody knew about is far better discovered on a quiet baseline draw than blamed, months later, on a compound that may have had nothing to do with it.

The metabolic markers peptides can move

Here is where the panel gets specific to why people are reading this. Fasting glucose and hemoglobin A1c together describe your blood-sugar control — the glucose is a snapshot, the A1c a rolling three-month average. They belong on nearly every peptide baseline because growth-hormone secretagogues can reduce insulin sensitivity. In human trials, MK-677 (ibutamoren) has been reported to raise fasting glucose and reduce insulin sensitivity in some participants, which is one of the clearest reasons that molecule stays investigational and unapproved for general use. Knowing your A1c before you start means that if it drifts from, say, 5.2 to 5.7, you can see it early and act, rather than discovering a prediabetic trend a year in.

Fasting insulin, drawn alongside glucose, lets a physician calculate HOMA-IR, a simple index of insulin resistance. It is not always ordered, but it is a genuinely useful before number for anyone considering a GH-axis peptide, precisely because that axis and insulin sensitivity are linked. A lipid panel — total cholesterol, LDL, HDL, triglycerides — rounds out the metabolic picture. Some GH-axis agents, tesamorelin in particular, were studied specifically for their effect on visceral fat and lipids, so a baseline lipid panel is both a safety marker and, for some, a measure of whether a goal is being met.

IGF-1 deserves its own sentence of respect. Insulin-like growth factor 1 is the downstream messenger of growth hormone, and it is the single most informative lab for anyone using a secretagogue. Growth hormone itself is released in pulses and is notoriously hard to measure from a single random draw; IGF-1 is far more stable and reflects the integrated GH effect over time. A baseline IGF-1 tells a physician where you sit relative to the age-adjusted range before any peptide, so that the goal becomes optimizing within a healthy band rather than blindly pushing a number as high as it will go. Chronically elevated IGF-1 is not a trophy; it is associated with real long-term concerns, which is why the before value and ongoing monitoring both matter.

Hormones, thyroid, and the sex-hormone panel

Peptides do not act in a vacuum; they sit inside your whole endocrine system, and a responsible baseline looks at the neighbors. A thyroid panel — at minimum TSH, and ideally free T4 and free T3 — matters because thyroid function shapes metabolism, energy, and body composition, the very outcomes people often attribute to peptides. An undiagnosed thyroid problem can masquerade as the symptoms someone hopes a peptide will fix, and it can also interact with how the GH axis behaves. Catching it first prevents months of misattribution.

For men, a sex-hormone look typically includes total and free testosterone, estradiol, SHBG, LH, and FSH. Many men exploring GH-axis peptides are also curious about testosterone optimization, and the two conversations are genuinely intertwined; a physician needs the baseline to keep them straight. For men over roughly 40, or younger men with risk factors or family history, a prostate-specific antigen (PSA) test is a standard part of any hormone-adjacent baseline, and it is one you do not want to skip. For women, the relevant panel depends heavily on age, cycle, and menopausal status, and is best individualized with a clinician rather than ordered off a generic list.

The extras worth discussing with your physician

Beyond the core, several add-on markers come up often enough to mention. A vitamin D level is worth checking; deficiency is common even in sunny Houston, because people spend the brutal months indoors in air conditioning, and low vitamin D drags on the very energy and recovery metrics people track. High-sensitivity CRP gives a read on systemic inflammation and adds cardiovascular context. Ferritin and a full iron panel deepen the anemia picture when the CBC hints at it. For anyone with cardiovascular risk, an ApoB or lipoprotein(a) can sharpen the lipid story well beyond a standard panel.

Whether any of these belong on your specific order is a physician-by-physician, patient-by-patient decision. The point is not to draw every tube the lab offers — that path leads to incidental findings and anxiety without added safety. The point is to match the panel to your goals, your history, and the particular peptide under discussion. A person eyeing tesamorelin for visceral fat has a different sensible panel than someone considering a healing-oriented peptide for a joint, and both differ from someone whose real question is metabolic.

• Complete blood count (CBC) — red cells, white cells, platelets; broad screen for anemia and infection.
• Comprehensive metabolic panel (CMP) — kidney and liver function, electrolytes, glucose.
• Fasting glucose and hemoglobin A1c — blood-sugar control, essential before GH-axis peptides.
• Fasting insulin and HOMA-IR — insulin-resistance depth for metabolically at-risk individuals.
• Lipid panel — cholesterol, LDL, HDL, triglycerides; safety plus effect for some agents.
• IGF-1 — the single most informative marker for secretagogue users.
• Thyroid panel — TSH at minimum, ideally free T4 and free T3.
• Sex hormones — total and free testosterone, estradiol, SHBG, LH, FSH; individualized for women.
• PSA — standard for men over ~40 or with risk factors.
• Optional add-ons — vitamin D, hs-CRP, ferritin and iron studies, ApoB or Lp(a) as indicated.

The Houston factor: heat, humidity, and how your labs read

Living on the Gulf Coast changes the practical mechanics of bloodwork in ways worth naming. Houston summers are not a minor inconvenience — weeks of high-90s heat and swamp humidity push people into chronic low-grade dehydration without their noticing. Hydration status genuinely affects several lab values. Dehydration can concentrate the blood, nudging hematocrit, BUN, sodium, and even creatinine in ways that can look like a problem but resolve with a glass of water. If you roll into a draw parched after a July afternoon in the Heights or a jobsite out in Katy, your baseline may not reflect your true normal.

The practical fix is boring and effective: hydrate well the day before and the morning of your draw, and try to standardize the conditions. If your baseline was fasted and hydrated at 8 a.m., your follow-ups should be too, so you are comparing like with like. This is not Houston-specific medicine — hydration matters everywhere — but the Gulf Coast climate makes the failure mode more common, and it is worth building into your routine from the first draw.

Houston also happens to sit next to one of the densest concentrations of medical expertise on the planet. The Texas Medical Center and the physicians, endocrinologists, and labs clustered around it mean that getting a thorough baseline and an informed second opinion is genuinely accessible here in a way it is not everywhere. Texas telehealth has also matured, and many Houston-area providers now handle intake and lab ordering remotely before an in-person visit. Texas permits physician-supervised compounding within its regulatory framework, which is part of why compounded peptides circulate in the local wellness scene — but circulation is not endorsement, and legality of a compounding pathway says nothing about whether a given peptide is proven, approved, or right for you.

A word on what is approved and what is not

Honesty about regulatory status is central to using any of this safely. The large majority of research peptides discussed online — including the growth-hormone secretagogues ipamorelin and MK-677 — are not FDA-approved for human use. They are sold and discussed as research compounds, the human evidence is often limited to small or older studies, and much of what circulates as protocol wisdom is anecdotal rather than trial-grade. That does not make them inherently sinister, but it does mean the burden of caution sits squarely on you and your physician, and that baseline monitoring is more important, not less.

A handful of peptide and peptide-adjacent drugs are FDA-approved, each for a specific indication. Tesamorelin is approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. The GLP-1 and dual-agonist drugs — semaglutide, tirzepatide, liraglutide — are approved for type 2 diabetes and, in specific formulations, chronic weight management. PT-141 (bremelanotide) is approved for certain cases of hypoactive sexual desire disorder. Approval for one indication is not a blanket endorsement for every use people put these to, and the approved agents still carry monitoring needs. The distinction between an FDA-approved drug used on-label and an investigational compound used experimentally is one your baseline labs help your physician navigate.

Putting it together with a physician

The through-line of this entire guide is that the labs are not the plan — they are the input to a conversation with someone qualified to interpret them. A good baseline visit looks like this: you bring your goals and history, the physician orders a panel matched to those goals and to any peptide under discussion, the results come back, and together you decide whether starting anything makes sense at all, or whether an abnormal finding needs attention first. Then, if a protocol does begin, the baseline becomes the yardstick for follow-up draws — commonly at some interval of weeks to months, at the physician's discretion — so that IGF-1, glucose, and the rest can be watched rather than guessed at.

That cadence of measure, act, re-measure is the difference between using these compounds as an informed adult with medical oversight and using them blind. It is unglamorous, it costs a little money and a couple of early mornings, and it is the single most protective thing you can do. In a city with the medical density of Houston, there is little excuse to skip it. Take the picture first. Then, and only then, have the real conversation about whether a peptide belongs in yours. The people who do this well are rarely the ones chasing the most aggressive protocol; they are the ones who treated the boring baseline as seriously as the exciting compound, and who gave a physician the data to keep them safe over months and years rather than weeks.